nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCB1—ovarian cancer	0.327	1	CbGaD
Canagliflozin—ABCC2—Paclitaxel—ovarian cancer	0.0769	0.162	CbGbCtD
Canagliflozin—ABCC2—Carboplatin—ovarian cancer	0.0724	0.152	CbGbCtD
Canagliflozin—ABCC2—Docetaxel—ovarian cancer	0.0556	0.117	CbGbCtD
Canagliflozin—ABCB1—Topotecan—ovarian cancer	0.0507	0.107	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—ovarian cancer	0.0415	0.0872	CbGbCtD
Canagliflozin—ABCB1—Vinorelbine—ovarian cancer	0.0357	0.0751	CbGbCtD
Canagliflozin—CYP3A4—Topotecan—ovarian cancer	0.0304	0.0639	CbGbCtD
Canagliflozin—ABCB1—Paclitaxel—ovarian cancer	0.0251	0.0528	CbGbCtD
Canagliflozin—CYP3A4—Vinorelbine—ovarian cancer	0.0214	0.045	CbGbCtD
Canagliflozin—ABCB1—Docetaxel—ovarian cancer	0.0181	0.0382	CbGbCtD
Canagliflozin—CYP3A4—Paclitaxel—ovarian cancer	0.015	0.0316	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—ovarian cancer	0.0135	0.0284	CbGbCtD
Canagliflozin—CYP3A4—Docetaxel—ovarian cancer	0.0109	0.0229	CbGbCtD
Canagliflozin—CYP3A4—Doxorubicin—ovarian cancer	0.0081	0.017	CbGbCtD
Canagliflozin—SLC5A1—epithelium—ovarian cancer	0.00374	0.128	CbGeAlD
Canagliflozin—SLC5A1—endometrium—ovarian cancer	0.00335	0.115	CbGeAlD
Canagliflozin—SLC5A2—vagina—ovarian cancer	0.00332	0.114	CbGeAlD
Canagliflozin—SLC5A2—testis—ovarian cancer	0.00296	0.101	CbGeAlD
Canagliflozin—SLC5A1—vagina—ovarian cancer	0.00251	0.086	CbGeAlD
Canagliflozin—SLC5A1—testis—ovarian cancer	0.00224	0.0768	CbGeAlD
Canagliflozin—Dapagliflozin—ABCB1—ovarian cancer	0.00175	1	CrCbGaD
Canagliflozin—ORM1—endometrium—ovarian cancer	0.00111	0.038	CbGeAlD
Canagliflozin—ORM1—female reproductive system—ovarian cancer	0.00092	0.0315	CbGeAlD
Canagliflozin—ORM1—bone marrow—ovarian cancer	0.000869	0.0297	CbGeAlD
Canagliflozin—Nocturia—Paclitaxel—ovarian cancer	0.000855	0.00667	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Epirubicin—ovarian cancer	0.00083	0.00647	CcSEcCtD
Canagliflozin—Blood creatinine increased—Vinorelbine—ovarian cancer	0.000802	0.00626	CcSEcCtD
Canagliflozin—Vulvovaginal candidiasis—Doxorubicin—ovarian cancer	0.000798	0.00623	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Doxorubicin—ovarian cancer	0.000768	0.00599	CcSEcCtD
Canagliflozin—ABCC2—female reproductive system—ovarian cancer	0.000756	0.0259	CbGeAlD
Canagliflozin—Serum creatinine increased—Epirubicin—ovarian cancer	0.000737	0.00575	CcSEcCtD
Canagliflozin—Pancreatitis—Vinorelbine—ovarian cancer	0.000725	0.00566	CcSEcCtD
Canagliflozin—Rash maculo-papular—Paclitaxel—ovarian cancer	0.000721	0.00562	CcSEcCtD
Canagliflozin—Urine output increased—Paclitaxel—ovarian cancer	0.000717	0.00559	CcSEcCtD
Canagliflozin—Serum creatinine increased—Doxorubicin—ovarian cancer	0.000682	0.00532	CcSEcCtD
Canagliflozin—Urinary tract disorder—Melphalan—ovarian cancer	0.000669	0.00522	CcSEcCtD
Canagliflozin—Urethral disorder—Melphalan—ovarian cancer	0.000665	0.00518	CcSEcCtD
Canagliflozin—Polyuria—Paclitaxel—ovarian cancer	0.000656	0.00512	CcSEcCtD
Canagliflozin—ALB—testis—ovarian cancer	0.000651	0.0223	CbGeAlD
Canagliflozin—Angiopathy—Topotecan—ovarian cancer	0.000628	0.0049	CcSEcCtD
Canagliflozin—Renal failure acute—Paclitaxel—ovarian cancer	0.000624	0.00487	CcSEcCtD
Canagliflozin—Angioedema—Chlorambucil—ovarian cancer	0.000619	0.00483	CcSEcCtD
Canagliflozin—ABCC2—testis—ovarian cancer	0.00061	0.0209	CbGeAlD
Canagliflozin—Malnutrition—Topotecan—ovarian cancer	0.000603	0.0047	CcSEcCtD
Canagliflozin—Rash erythematous—Epirubicin—ovarian cancer	0.000592	0.00462	CcSEcCtD
Canagliflozin—Hypoglycaemia—Paclitaxel—ovarian cancer	0.00059	0.0046	CcSEcCtD
Canagliflozin—Convulsion—Chlorambucil—ovarian cancer	0.000587	0.00458	CcSEcCtD
Canagliflozin—Rash pustular—Epirubicin—ovarian cancer	0.000569	0.00444	CcSEcCtD
Canagliflozin—Angioedema—Topotecan—ovarian cancer	0.000551	0.0043	CcSEcCtD
Canagliflozin—Infection—Chlorambucil—ovarian cancer	0.000549	0.00428	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—ovarian cancer	0.000548	0.00427	CcSEcCtD
Canagliflozin—Blood creatinine increased—Paclitaxel—ovarian cancer	0.000539	0.00421	CcSEcCtD
Canagliflozin—ORM1—lymph node—ovarian cancer	0.000538	0.0184	CbGeAlD
Canagliflozin—Angiopathy—Vinorelbine—ovarian cancer	0.000537	0.00419	CcSEcCtD
Canagliflozin—Dehydration—Paclitaxel—ovarian cancer	0.000536	0.00418	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—ovarian cancer	0.000526	0.0041	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Paclitaxel—ovarian cancer	0.000526	0.0041	CcSEcCtD
Canagliflozin—Breast disorder—Paclitaxel—ovarian cancer	0.00052	0.00406	CcSEcCtD
Canagliflozin—Malnutrition—Vinorelbine—ovarian cancer	0.000516	0.00402	CcSEcCtD
Canagliflozin—Erythema—Vinorelbine—ovarian cancer	0.000516	0.00402	CcSEcCtD
Canagliflozin—Convulsion—Melphalan—ovarian cancer	0.000511	0.00399	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00051	0.00397	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000499	0.00389	CcSEcCtD
Canagliflozin—Nocturia—Epirubicin—ovarian cancer	0.000489	0.00381	CcSEcCtD
Canagliflozin—Infection—Topotecan—ovarian cancer	0.000489	0.00381	CcSEcCtD
Canagliflozin—Pancreatitis—Paclitaxel—ovarian cancer	0.000488	0.00381	CcSEcCtD
Canagliflozin—Nervous system disorder—Topotecan—ovarian cancer	0.000482	0.00376	CcSEcCtD
Canagliflozin—Infection—Melphalan—ovarian cancer	0.000478	0.00373	CcSEcCtD
Canagliflozin—Skin disorder—Topotecan—ovarian cancer	0.000478	0.00373	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000477	0.00372	CcSEcCtD
Canagliflozin—Fatigue—Chlorambucil—ovarian cancer	0.000476	0.00372	CcSEcCtD
Canagliflozin—ALB—lymph node—ovarian cancer	0.000472	0.0162	CbGeAlD
Canagliflozin—Angioedema—Vinorelbine—ovarian cancer	0.000471	0.00367	CcSEcCtD
Canagliflozin—Skin disorder—Melphalan—ovarian cancer	0.000468	0.00365	CcSEcCtD
Canagliflozin—ABCB1—myometrium—ovarian cancer	0.000466	0.016	CbGeAlD
Canagliflozin—Pollakiuria—Paclitaxel—ovarian cancer	0.00046	0.00359	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.000454	0.00354	CcSEcCtD
Canagliflozin—Dehydration—Docetaxel—ovarian cancer	0.000454	0.00354	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—ovarian cancer	0.000452	0.00353	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000452	0.00352	CcSEcCtD
Canagliflozin—Hypotension—Melphalan—ovarian cancer	0.00045	0.00351	CcSEcCtD
Canagliflozin—ABCB1—embryo—ovarian cancer	0.000449	0.0154	CbGeAlD
Canagliflozin—Orthostatic hypotension—Docetaxel—ovarian cancer	0.000446	0.00348	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—ovarian cancer	0.000446	0.00348	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—ovarian cancer	0.000443	0.00346	CcSEcCtD
Canagliflozin—ABCC2—lymph node—ovarian cancer	0.000442	0.0151	CbGeAlD
Canagliflozin—Breast disorder—Docetaxel—ovarian cancer	0.000441	0.00344	CcSEcCtD
Canagliflozin—Urticaria—Chlorambucil—ovarian cancer	0.000439	0.00342	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—ovarian cancer	0.000438	0.00342	CcSEcCtD
Canagliflozin—Abdominal pain—Chlorambucil—ovarian cancer	0.000437	0.00341	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000436	0.0034	CcSEcCtD
Canagliflozin—Urinary tract infection—Paclitaxel—ovarian cancer	0.000431	0.00336	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—ovarian cancer	0.000428	0.00334	CcSEcCtD
Canagliflozin—Vaginal infection—Epirubicin—ovarian cancer	0.000428	0.00334	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000425	0.00331	CcSEcCtD
Canagliflozin—Fatigue—Topotecan—ovarian cancer	0.000424	0.00331	CcSEcCtD
Canagliflozin—Constipation—Topotecan—ovarian cancer	0.000421	0.00328	CcSEcCtD
Canagliflozin—Infection—Vinorelbine—ovarian cancer	0.000418	0.00326	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000416	0.00324	CcSEcCtD
Canagliflozin—Fatigue—Melphalan—ovarian cancer	0.000415	0.00324	CcSEcCtD
Canagliflozin—Nervous system disorder—Vinorelbine—ovarian cancer	0.000413	0.00322	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—ovarian cancer	0.000412	0.00322	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—ovarian cancer	0.000412	0.00322	CcSEcCtD
Canagliflozin—Bladder pain—Epirubicin—ovarian cancer	0.00041	0.0032	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—ovarian cancer	0.00041	0.0032	CcSEcCtD
Canagliflozin—Skin disorder—Vinorelbine—ovarian cancer	0.000409	0.00319	CcSEcCtD
Canagliflozin—Hypersensitivity—Chlorambucil—ovarian cancer	0.000407	0.00318	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—ovarian cancer	0.000405	0.00316	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Topotecan—ovarian cancer	0.000402	0.00314	CcSEcCtD
Canagliflozin—Asthenia—Chlorambucil—ovarian cancer	0.000396	0.00309	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—ovarian cancer	0.000396	0.00309	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—ovarian cancer	0.000396	0.00309	CcSEcCtD
Canagliflozin—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000393	0.00307	CcSEcCtD
Canagliflozin—Hypotension—Vinorelbine—ovarian cancer	0.000393	0.00307	CcSEcCtD
Canagliflozin—Pruritus—Chlorambucil—ovarian cancer	0.000391	0.00305	CcSEcCtD
Canagliflozin—Urticaria—Topotecan—ovarian cancer	0.000391	0.00305	CcSEcCtD
Canagliflozin—Urethral disorder—Paclitaxel—ovarian cancer	0.000391	0.00305	CcSEcCtD
Canagliflozin—Abdominal pain—Topotecan—ovarian cancer	0.000389	0.00303	CcSEcCtD
Canagliflozin—CYP3A4—female reproductive system—ovarian cancer	0.000384	0.0132	CbGeAlD
Canagliflozin—Urticaria—Melphalan—ovarian cancer	0.000383	0.00298	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—ovarian cancer	0.000381	0.00298	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—ovarian cancer	0.000379	0.00296	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—ovarian cancer	0.000378	0.00295	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—ovarian cancer	0.000375	0.00292	CcSEcCtD
Canagliflozin—ABCB1—epithelium—ovarian cancer	0.000366	0.0125	CbGeAlD
Canagliflozin—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000363	0.00283	CcSEcCtD
Canagliflozin—ABCB1—uterine cervix—ovarian cancer	0.000363	0.0124	CbGeAlD
Canagliflozin—Fatigue—Vinorelbine—ovarian cancer	0.000363	0.00283	CcSEcCtD
Canagliflozin—Hypersensitivity—Topotecan—ovarian cancer	0.000362	0.00283	CcSEcCtD
Canagliflozin—Angiopathy—Paclitaxel—ovarian cancer	0.000361	0.00282	CcSEcCtD
Canagliflozin—Constipation—Vinorelbine—ovarian cancer	0.00036	0.00281	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—ovarian cancer	0.000357	0.00278	CcSEcCtD
Canagliflozin—Hypersensitivity—Melphalan—ovarian cancer	0.000355	0.00277	CcSEcCtD
Canagliflozin—Asthenia—Topotecan—ovarian cancer	0.000353	0.00275	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—ovarian cancer	0.00035	0.00273	CcSEcCtD
Canagliflozin—Pruritus—Topotecan—ovarian cancer	0.000348	0.00271	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—ovarian cancer	0.000347	0.00271	CcSEcCtD
Canagliflozin—Erythema—Paclitaxel—ovarian cancer	0.000347	0.00271	CcSEcCtD
Canagliflozin—Malnutrition—Paclitaxel—ovarian cancer	0.000347	0.00271	CcSEcCtD
Canagliflozin—ABCB1—decidua—ovarian cancer	0.000346	0.0118	CbGeAlD
Canagliflozin—Asthenia—Melphalan—ovarian cancer	0.000346	0.0027	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000344	0.00268	CcSEcCtD
Canagliflozin—Pruritus—Melphalan—ovarian cancer	0.000341	0.00266	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—ovarian cancer	0.000337	0.00263	CcSEcCtD
Canagliflozin—Urticaria—Vinorelbine—ovarian cancer	0.000334	0.00261	CcSEcCtD
Canagliflozin—Urinary tract disorder—Docetaxel—ovarian cancer	0.000333	0.0026	CcSEcCtD
Canagliflozin—Abdominal pain—Vinorelbine—ovarian cancer	0.000333	0.00259	CcSEcCtD
Canagliflozin—Urethral disorder—Docetaxel—ovarian cancer	0.000331	0.00258	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—ovarian cancer	0.00033	0.00257	CcSEcCtD
Canagliflozin—ABCB1—endometrium—ovarian cancer	0.000328	0.0112	CbGeAlD
Canagliflozin—Nausea—Chlorambucil—ovarian cancer	0.000328	0.00256	CcSEcCtD
Canagliflozin—Dizziness—Topotecan—ovarian cancer	0.000325	0.00254	CcSEcCtD
Canagliflozin—Angioedema—Paclitaxel—ovarian cancer	0.000317	0.00247	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000312	0.00243	CcSEcCtD
Canagliflozin—Syncope—Paclitaxel—ovarian cancer	0.000311	0.00243	CcSEcCtD
Canagliflozin—Rash—Topotecan—ovarian cancer	0.00031	0.00242	CcSEcCtD
Canagliflozin—Hypersensitivity—Vinorelbine—ovarian cancer	0.00031	0.00242	CcSEcCtD
Canagliflozin—Dermatitis—Topotecan—ovarian cancer	0.00031	0.00242	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—ovarian cancer	0.000308	0.00241	CcSEcCtD
Canagliflozin—Angiopathy—Docetaxel—ovarian cancer	0.000306	0.00239	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—ovarian cancer	0.000306	0.00239	CcSEcCtD
Canagliflozin—Loss of consciousness—Paclitaxel—ovarian cancer	0.000305	0.00238	CcSEcCtD
Canagliflozin—ABCB1—gonad—ovarian cancer	0.000304	0.0104	CbGeAlD
Canagliflozin—Rash—Melphalan—ovarian cancer	0.000304	0.00237	CcSEcCtD
Canagliflozin—Dermatitis—Melphalan—ovarian cancer	0.000303	0.00237	CcSEcCtD
Canagliflozin—ABCB1—uterus—ovarian cancer	0.000302	0.0104	CbGeAlD
Canagliflozin—Asthenia—Vinorelbine—ovarian cancer	0.000302	0.00235	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000301	0.00235	CcSEcCtD
Canagliflozin—Convulsion—Paclitaxel—ovarian cancer	0.0003	0.00234	CcSEcCtD
Canagliflozin—Pruritus—Vinorelbine—ovarian cancer	0.000298	0.00232	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—ovarian cancer	0.000298	0.00232	CcSEcCtD
Canagliflozin—Malnutrition—Docetaxel—ovarian cancer	0.000294	0.00229	CcSEcCtD
Canagliflozin—Erythema—Docetaxel—ovarian cancer	0.000294	0.00229	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000293	0.00229	CcSEcCtD
Canagliflozin—Nausea—Topotecan—ovarian cancer	0.000292	0.00228	CcSEcCtD
Canagliflozin—Dry mouth—Paclitaxel—ovarian cancer	0.000289	0.00225	CcSEcCtD
Canagliflozin—Nausea—Melphalan—ovarian cancer	0.000286	0.00223	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000285	0.00223	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—ovarian cancer	0.000283	0.00221	CcSEcCtD
Canagliflozin—Infection—Paclitaxel—ovarian cancer	0.000281	0.00219	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—ovarian cancer	0.000279	0.00218	CcSEcCtD
Canagliflozin—Shock—Paclitaxel—ovarian cancer	0.000278	0.00217	CcSEcCtD
Canagliflozin—Dizziness—Vinorelbine—ovarian cancer	0.000278	0.00217	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000278	0.00217	CcSEcCtD
Canagliflozin—Nervous system disorder—Paclitaxel—ovarian cancer	0.000278	0.00217	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—ovarian cancer	0.000275	0.00215	CcSEcCtD
Canagliflozin—Skin disorder—Paclitaxel—ovarian cancer	0.000275	0.00214	CcSEcCtD
Canagliflozin—ABCB1—female reproductive system—ovarian cancer	0.000272	0.00931	CbGeAlD
Canagliflozin—Rash—Vinorelbine—ovarian cancer	0.000265	0.00207	CcSEcCtD
Canagliflozin—Dermatitis—Vinorelbine—ovarian cancer	0.000265	0.00207	CcSEcCtD
Canagliflozin—Hypotension—Paclitaxel—ovarian cancer	0.000264	0.00206	CcSEcCtD
Canagliflozin—Syncope—Docetaxel—ovarian cancer	0.000264	0.00206	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—ovarian cancer	0.000263	0.00205	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00026	0.00203	CcSEcCtD
Canagliflozin—Loss of consciousness—Docetaxel—ovarian cancer	0.000258	0.00202	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—ovarian cancer	0.000258	0.00201	CcSEcCtD
Canagliflozin—ABCB1—bone marrow—ovarian cancer	0.000257	0.00879	CbGeAlD
Canagliflozin—Convulsion—Docetaxel—ovarian cancer	0.000255	0.00199	CcSEcCtD
Canagliflozin—Nausea—Vinorelbine—ovarian cancer	0.00025	0.00195	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000249	0.00194	CcSEcCtD
Canagliflozin—ABCB1—female gonad—ovarian cancer	0.000247	0.00847	CbGeAlD
Canagliflozin—Urinary tract infection—Epirubicin—ovarian cancer	0.000247	0.00192	CcSEcCtD
Canagliflozin—ABCB1—vagina—ovarian cancer	0.000246	0.00842	CbGeAlD
Canagliflozin—Dry mouth—Docetaxel—ovarian cancer	0.000245	0.00191	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000244	0.00191	CcSEcCtD
Canagliflozin—Fatigue—Paclitaxel—ovarian cancer	0.000244	0.0019	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—ovarian cancer	0.000243	0.0019	CcSEcCtD
Canagliflozin—Constipation—Paclitaxel—ovarian cancer	0.000242	0.00189	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.00024	0.00187	CcSEcCtD
Canagliflozin—Infection—Docetaxel—ovarian cancer	0.000238	0.00186	CcSEcCtD
Canagliflozin—Shock—Docetaxel—ovarian cancer	0.000236	0.00184	CcSEcCtD
Canagliflozin—Nervous system disorder—Docetaxel—ovarian cancer	0.000235	0.00184	CcSEcCtD
Canagliflozin—Skin disorder—Docetaxel—ovarian cancer	0.000233	0.00182	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000231	0.00181	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—ovarian cancer	0.000228	0.00178	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—ovarian cancer	0.000225	0.00175	CcSEcCtD
Canagliflozin—Urticaria—Paclitaxel—ovarian cancer	0.000225	0.00175	CcSEcCtD
Canagliflozin—Hypotension—Docetaxel—ovarian cancer	0.000224	0.00175	CcSEcCtD
Canagliflozin—Abdominal pain—Paclitaxel—ovarian cancer	0.000224	0.00175	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—ovarian cancer	0.000223	0.00174	CcSEcCtD
Canagliflozin—ABCB1—testis—ovarian cancer	0.000219	0.00751	CbGeAlD
Canagliflozin—Hypersensitivity—Paclitaxel—ovarian cancer	0.000209	0.00163	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000208	0.00162	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000207	0.00162	CcSEcCtD
Canagliflozin—Fatigue—Docetaxel—ovarian cancer	0.000207	0.00161	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—ovarian cancer	0.000207	0.00161	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—ovarian cancer	0.000207	0.00161	CcSEcCtD
Canagliflozin—Constipation—Docetaxel—ovarian cancer	0.000205	0.0016	CcSEcCtD
Canagliflozin—Asthenia—Paclitaxel—ovarian cancer	0.000203	0.00158	CcSEcCtD
Canagliflozin—Pruritus—Paclitaxel—ovarian cancer	0.0002	0.00156	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—ovarian cancer	0.000198	0.00155	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—ovarian cancer	0.000198	0.00155	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000196	0.00153	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—ovarian cancer	0.000191	0.00149	CcSEcCtD
Canagliflozin—Abdominal pain—Docetaxel—ovarian cancer	0.00019	0.00148	CcSEcCtD
Canagliflozin—Dizziness—Paclitaxel—ovarian cancer	0.000187	0.00146	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—ovarian cancer	0.000183	0.00143	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—ovarian cancer	0.000183	0.00143	CcSEcCtD
Canagliflozin—Rash—Paclitaxel—ovarian cancer	0.000178	0.00139	CcSEcCtD
Canagliflozin—Dermatitis—Paclitaxel—ovarian cancer	0.000178	0.00139	CcSEcCtD
Canagliflozin—Syncope—Epirubicin—ovarian cancer	0.000178	0.00139	CcSEcCtD
Canagliflozin—Hypersensitivity—Docetaxel—ovarian cancer	0.000177	0.00138	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—ovarian cancer	0.000174	0.00136	CcSEcCtD
Canagliflozin—Asthenia—Docetaxel—ovarian cancer	0.000172	0.00134	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—ovarian cancer	0.000172	0.00134	CcSEcCtD
Canagliflozin—Pruritus—Docetaxel—ovarian cancer	0.00017	0.00132	CcSEcCtD
Canagliflozin—Nausea—Paclitaxel—ovarian cancer	0.000168	0.00131	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000168	0.00131	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—ovarian cancer	0.000165	0.00129	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—ovarian cancer	0.000165	0.00128	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—ovarian cancer	0.000161	0.00126	CcSEcCtD
Canagliflozin—Infection—Epirubicin—ovarian cancer	0.000161	0.00125	CcSEcCtD
Canagliflozin—Shock—Epirubicin—ovarian cancer	0.000159	0.00124	CcSEcCtD
Canagliflozin—ABCB1—lymph node—ovarian cancer	0.000159	0.00545	CbGeAlD
Canagliflozin—Convulsion—Doxorubicin—ovarian cancer	0.000159	0.00124	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—ovarian cancer	0.000159	0.00124	CcSEcCtD
Canagliflozin—Dizziness—Docetaxel—ovarian cancer	0.000159	0.00124	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—ovarian cancer	0.000157	0.00123	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000155	0.00121	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—ovarian cancer	0.000153	0.00119	CcSEcCtD
Canagliflozin—Rash—Docetaxel—ovarian cancer	0.000151	0.00118	CcSEcCtD
Canagliflozin—Hypotension—Epirubicin—ovarian cancer	0.000151	0.00118	CcSEcCtD
Canagliflozin—Dermatitis—Docetaxel—ovarian cancer	0.000151	0.00118	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—ovarian cancer	0.000149	0.00116	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—ovarian cancer	0.000147	0.00115	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—ovarian cancer	0.000147	0.00115	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—ovarian cancer	0.000145	0.00113	CcSEcCtD
Canagliflozin—Nausea—Docetaxel—ovarian cancer	0.000142	0.00111	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—ovarian cancer	0.00014	0.00109	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00014	0.00109	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—ovarian cancer	0.00014	0.00109	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—ovarian cancer	0.000138	0.00108	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000132	0.00103	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000129	0.00101	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—ovarian cancer	0.000129	0.00101	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—ovarian cancer	0.000129	0.001	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—ovarian cancer	0.000128	0.000999	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—ovarian cancer	0.000128	0.000998	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000122	0.000955	CcSEcCtD
Canagliflozin—Hypersensitivity—Epirubicin—ovarian cancer	0.000119	0.00093	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—ovarian cancer	0.000119	0.000928	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—ovarian cancer	0.000118	0.000923	CcSEcCtD
Canagliflozin—Asthenia—Epirubicin—ovarian cancer	0.000116	0.000906	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—ovarian cancer	0.000114	0.000893	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—ovarian cancer	0.00011	0.00086	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—ovarian cancer	0.000107	0.000838	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—ovarian cancer	0.000107	0.000835	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—ovarian cancer	0.000106	0.000826	CcSEcCtD
Canagliflozin—Rash—Epirubicin—ovarian cancer	0.000102	0.000796	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—ovarian cancer	0.000102	0.000795	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—ovarian cancer	9.9e-05	0.000772	CcSEcCtD
Canagliflozin—Nausea—Epirubicin—ovarian cancer	9.61e-05	0.00075	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—ovarian cancer	9.44e-05	0.000736	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—ovarian cancer	9.43e-05	0.000736	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—ovarian cancer	8.89e-05	0.000694	CcSEcCtD
Canagliflozin—SLC5A1—Disease—TERT—ovarian cancer	5.92e-05	0.00154	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TERT—ovarian cancer	5.92e-05	0.00154	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—SLC5A5—ovarian cancer	5.87e-05	0.00153	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ABCB1—ovarian cancer	5.8e-05	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ABCB1—ovarian cancer	5.8e-05	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TYMS—ovarian cancer	5.69e-05	0.00148	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TYMS—ovarian cancer	5.69e-05	0.00148	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—SLC2A1—ovarian cancer	5.67e-05	0.00147	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL2—ovarian cancer	5.54e-05	0.00144	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CAV1—ovarian cancer	5.48e-05	0.00142	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CAV1—ovarian cancer	5.48e-05	0.00142	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	5.45e-05	0.00142	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP1B1—ovarian cancer	5.44e-05	0.00141	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6ST—ovarian cancer	5.19e-05	0.00135	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6ST—ovarian cancer	5.19e-05	0.00135	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APC—ovarian cancer	4.99e-05	0.0013	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APC—ovarian cancer	4.99e-05	0.0013	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	4.98e-05	0.00129	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.96e-05	0.00129	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PPP2R1A—ovarian cancer	4.82e-05	0.00125	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	4.81e-05	0.00125	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—AQP3—ovarian cancer	4.8e-05	0.00125	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	4.78e-05	0.00124	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.75e-05	0.00123	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	4.67e-05	0.00121	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYTB—ovarian cancer	4.62e-05	0.0012	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	4.62e-05	0.0012	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.61e-05	0.0012	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CAV1—ovarian cancer	4.59e-05	0.00119	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CAV1—ovarian cancer	4.59e-05	0.00119	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.53e-05	0.00118	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.52e-05	0.00117	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	4.49e-05	0.00117	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ABCB1—ovarian cancer	4.48e-05	0.00116	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TYMS—ovarian cancer	4.4e-05	0.00114	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	4.4e-05	0.00114	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CD—ovarian cancer	4.39e-05	0.00114	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CD—ovarian cancer	4.39e-05	0.00114	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.37e-05	0.00114	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	4.22e-05	0.0011	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	4.21e-05	0.00109	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CASP3—ovarian cancer	4.21e-05	0.00109	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2—ovarian cancer	4.2e-05	0.00109	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CG—ovarian cancer	4.18e-05	0.00109	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CG—ovarian cancer	4.18e-05	0.00109	CbGpPWpGaD
Canagliflozin—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	4.15e-05	0.00108	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	4.12e-05	0.00107	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	4.09e-05	0.00106	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPP1CC—ovarian cancer	4.04e-05	0.00105	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—BRIP1—ovarian cancer	4.04e-05	0.00105	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.04e-05	0.00105	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—ovarian cancer	4.03e-05	0.00105	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	4.01e-05	0.00104	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL6—ovarian cancer	4e-05	0.00104	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB2—ovarian cancer	3.87e-05	0.00101	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB2—ovarian cancer	3.87e-05	0.00101	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—ovarian cancer	3.84e-05	0.000999	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MTOR—ovarian cancer	3.82e-05	0.000994	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MTOR—ovarian cancer	3.82e-05	0.000994	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CB—ovarian cancer	3.82e-05	0.000994	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CB—ovarian cancer	3.82e-05	0.000994	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NME2—ovarian cancer	3.76e-05	0.000976	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CD—ovarian cancer	3.67e-05	0.000955	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CD—ovarian cancer	3.67e-05	0.000955	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.64e-05	0.000946	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1B—ovarian cancer	3.59e-05	0.000933	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1B—ovarian cancer	3.59e-05	0.000933	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	3.57e-05	0.000928	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—ovarian cancer	3.56e-05	0.000924	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CAV1—ovarian cancer	3.54e-05	0.000921	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.45e-05	0.000897	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CTNNB1—ovarian cancer	3.39e-05	0.000881	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CTNNB1—ovarian cancer	3.39e-05	0.000881	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	3.33e-05	0.000864	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTEN—ovarian cancer	3.3e-05	0.000859	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTEN—ovarian cancer	3.3e-05	0.000859	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NME2—ovarian cancer	3.29e-05	0.000855	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.28e-05	0.000852	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—ovarian cancer	3.25e-05	0.000846	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CG—ovarian cancer	3.23e-05	0.000839	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CB—ovarian cancer	3.2e-05	0.000832	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CB—ovarian cancer	3.2e-05	0.000832	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.19e-05	0.000829	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SPARC—ovarian cancer	3.19e-05	0.000828	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.19e-05	0.000828	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	3.12e-05	0.00081	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	2.99e-05	0.000777	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—ovarian cancer	2.96e-05	0.000768	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—ovarian cancer	2.96e-05	0.000768	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NRAS—ovarian cancer	2.95e-05	0.000766	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NRAS—ovarian cancer	2.95e-05	0.000766	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	2.95e-05	0.000766	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.94e-05	0.000765	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CD—ovarian cancer	2.84e-05	0.000737	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK3—ovarian cancer	2.82e-05	0.000734	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK3—ovarian cancer	2.82e-05	0.000734	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTEN—ovarian cancer	2.77e-05	0.000719	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTEN—ovarian cancer	2.77e-05	0.000719	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—ovarian cancer	2.75e-05	0.000714	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—ovarian cancer	2.75e-05	0.000714	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—YAP1—ovarian cancer	2.71e-05	0.000704	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK1—ovarian cancer	2.69e-05	0.000698	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK1—ovarian cancer	2.69e-05	0.000698	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—ovarian cancer	2.69e-05	0.000698	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—ovarian cancer	2.69e-05	0.000698	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.68e-05	0.000697	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	2.63e-05	0.000684	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	2.63e-05	0.000683	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.6e-05	0.000675	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	2.59e-05	0.000672	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—ovarian cancer	2.54e-05	0.000659	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—ovarian cancer	2.54e-05	0.000659	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CB—ovarian cancer	2.47e-05	0.000643	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.43e-05	0.000631	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYTB—ovarian cancer	2.42e-05	0.000629	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.37e-05	0.000615	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.36e-05	0.000613	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.35e-05	0.00061	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—ovarian cancer	2.33e-05	0.000606	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—ovarian cancer	2.33e-05	0.000606	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SOD1—ovarian cancer	2.32e-05	0.000602	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PPP2R1A—ovarian cancer	2.3e-05	0.000599	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	2.29e-05	0.000596	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.29e-05	0.000594	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—FASN—ovarian cancer	2.21e-05	0.000574	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC5A5—ovarian cancer	2.17e-05	0.000565	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HRAS—ovarian cancer	2.16e-05	0.00056	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HRAS—ovarian cancer	2.16e-05	0.00056	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—ovarian cancer	2.14e-05	0.000555	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.13e-05	0.000553	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYTB—ovarian cancer	2.12e-05	0.000551	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.12e-05	0.000551	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPP1CC—ovarian cancer	2.12e-05	0.00055	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BRIP1—ovarian cancer	2.12e-05	0.00055	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	2.11e-05	0.000547	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC2A1—ovarian cancer	2.1e-05	0.000545	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.08e-05	0.00054	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—ovarian cancer	2.06e-05	0.000536	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—ovarian cancer	2.06e-05	0.000536	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.06e-05	0.000534	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.05e-05	0.000534	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NME2—ovarian cancer	2.03e-05	0.000527	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.02e-05	0.000525	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1B1—ovarian cancer	2.01e-05	0.000523	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2e-05	0.00052	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—ovarian cancer	1.95e-05	0.000507	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—ovarian cancer	1.95e-05	0.000507	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	1.95e-05	0.000507	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—AKT1—ovarian cancer	1.9e-05	0.000495	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—AKT1—ovarian cancer	1.9e-05	0.000495	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPP1CC—ovarian cancer	1.85e-05	0.000482	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BRIP1—ovarian cancer	1.85e-05	0.000482	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.85e-05	0.000481	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	1.79e-05	0.000465	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PPP2R1A—ovarian cancer	1.78e-05	0.000464	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.78e-05	0.000461	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.76e-05	0.000458	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CAV1—ovarian cancer	1.69e-05	0.00044	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	1.69e-05	0.00044	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.67e-05	0.000433	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—ovarian cancer	1.66e-05	0.000431	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TYMS—ovarian cancer	1.63e-05	0.000423	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.62e-05	0.000421	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	1.61e-05	0.000419	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AKT1—ovarian cancer	1.59e-05	0.000414	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AKT1—ovarian cancer	1.59e-05	0.000414	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.59e-05	0.000412	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.59e-05	0.000412	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—ovarian cancer	1.54e-05	0.000401	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.54e-05	0.000401	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—ovarian cancer	1.51e-05	0.000392	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.5e-05	0.000389	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—YAP1—ovarian cancer	1.42e-05	0.000369	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.4e-05	0.000365	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	1.4e-05	0.000363	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.38e-05	0.000358	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CD—ovarian cancer	1.36e-05	0.000352	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.33e-05	0.000346	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CAV1—ovarian cancer	1.31e-05	0.000341	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYTB—ovarian cancer	1.31e-05	0.000339	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.25e-05	0.000326	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—YAP1—ovarian cancer	1.24e-05	0.000323	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.23e-05	0.000321	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AKT1—ovarian cancer	1.23e-05	0.00032	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—ovarian cancer	1.19e-05	0.00031	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CB—ovarian cancer	1.18e-05	0.000307	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FASN—ovarian cancer	1.16e-05	0.000301	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.14e-05	0.000297	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.14e-05	0.000297	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.14e-05	0.000297	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC5A5—ovarian cancer	1.14e-05	0.000296	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.12e-05	0.000292	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A1—ovarian cancer	1.1e-05	0.000286	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—ovarian cancer	1.09e-05	0.000282	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.08e-05	0.00028	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1B1—ovarian cancer	1.05e-05	0.000274	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CD—ovarian cancer	1.05e-05	0.000273	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FASN—ovarian cancer	1.01e-05	0.000263	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC5A5—ovarian cancer	9.97e-06	0.000259	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A1—ovarian cancer	9.63e-06	0.00025	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPP2R1A—ovarian cancer	9.34e-06	0.000243	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.3e-06	0.000242	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1B1—ovarian cancer	9.23e-06	0.00024	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—ovarian cancer	9.22e-06	0.00024	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CB—ovarian cancer	9.15e-06	0.000238	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NRAS—ovarian cancer	9.11e-06	0.000237	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—ovarian cancer	8.73e-06	0.000227	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—ovarian cancer	8.67e-06	0.000225	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TYMS—ovarian cancer	8.52e-06	0.000221	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK1—ovarian cancer	8.3e-06	0.000216	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPP2R1A—ovarian cancer	8.19e-06	0.000213	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—ovarian cancer	7.91e-06	0.000205	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—ovarian cancer	7.84e-06	0.000204	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—YAP1—ovarian cancer	7.66e-06	0.000199	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TYMS—ovarian cancer	7.46e-06	0.000194	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—ovarian cancer	7.2e-06	0.000187	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—ovarian cancer	6.97e-06	0.000181	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CAV1—ovarian cancer	6.86e-06	0.000178	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HRAS—ovarian cancer	6.67e-06	0.000173	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.56e-06	0.00017	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—ovarian cancer	6.25e-06	0.000162	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FASN—ovarian cancer	6.24e-06	0.000162	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A5—ovarian cancer	6.14e-06	0.00016	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CAV1—ovarian cancer	6.01e-06	0.000156	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.93e-06	0.000154	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—AKT1—ovarian cancer	5.89e-06	0.000153	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.69e-06	0.000148	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—ovarian cancer	5.58e-06	0.000145	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CD—ovarian cancer	5.5e-06	0.000143	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.48e-06	0.000142	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.04e-06	0.000131	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.82e-06	0.000125	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CB—ovarian cancer	4.79e-06	0.000125	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.68e-06	0.000122	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TYMS—ovarian cancer	4.6e-06	0.00012	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AKT1—ovarian cancer	4.56e-06	0.000118	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.2e-06	0.000109	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—ovarian cancer	4.14e-06	0.000108	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CAV1—ovarian cancer	3.71e-06	9.63e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—ovarian cancer	3.63e-06	9.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.38e-06	8.77e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.97e-06	7.71e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—ovarian cancer	2.92e-06	7.59e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.59e-06	6.72e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.56e-06	6.65e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AKT1—ovarian cancer	2.39e-06	6.2e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—ovarian cancer	2.23e-06	5.81e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AKT1—ovarian cancer	2.09e-06	5.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.58e-06	4.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AKT1—ovarian cancer	1.29e-06	3.35e-05	CbGpPWpGaD
